At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Prasugrel 10 mg daily x 2 weeks +1 moredrug
Likely dose
Prasugrel 10 mg daily x 2 weeksfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure
In Brief
A Phase 4 clinical trial evaluating Prasugrel 10 mg daily x 2 weeks and Clopidogrel 75 mg daily x 2 weeks for Systolic Heart Failure. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The investigators aim to determine if patients with systolic heart failure treated with prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystolic Heart Failure
CountriesUnited States
CollaboratorsDaiichi Sankyo, Eli Lilly and Company
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartMay 2013
Primary CompletionDec 2015
Study CompletionDec 2015
TodayJul 2026
First PostedJan 10, 2013
Enrollment StartMay 15, 2013
Primary CompletionDec 1, 2015
Study CompletionDec 28, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.5 years ago
Interventions
Prasugrel 10 mg daily x 2 weeksdrug
Clopidogrel 75 mg daily x 2 weeksdrug